Technicals

What Makes Apollo Investment (AINV) a New Strong Buy Stock

Apollo Investment (AINV) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates — one of the most powerful forces impacting stock prices — has triggered this rating change. A company’s changing earnings picture is at the core of the Zacks rating. […]

Technicals

Earnings Preview: AngioDynamics (ANGO) Q2 Earnings Expected to Decline

Wall Street expects a year-over-year decline in earnings on lower revenues when AngioDynamics (ANGO) reports results for the quarter ended November 2019. While this widely-known consensus outlook is important in gauging the company’s earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on January 7. […]

Technicals

Exfo (EXFO) Earnings Expected to Grow: What to Know Ahead of Next Week’s Release

Wall Street expects a year-over-year increase in earnings on higher revenues when Exfo (EXFO) reports results for the quarter ended November 2019. While this widely-known consensus outlook is important in gauging the company’s earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on January 7, 2020, might help the stock move higher if these key numbers are better than expectations. […]

Stock Analysts

Here’s Why You Should Hold on to Insulet (PODD) Stock Now

Insulet Corporation PODD has been progressing well with respect to its four-pronged strategy and already seems on track to achieve revenues of $1 billion by 2021. The four key initiatives are expanding Omnipod’s market access, executing on its innovation roadmap, building the U.S. manufacturing facility and implementing its plan to sell directly in Europe. […]

Stock Analysts

Jazz Enrolls First Patient in Phase II/III Leukemia Study

Jazz Pharmaceuticals plc JAZZ announced that it has enrolled the first patient in the pivotal phase II/III study evaluating its novel asparaginase JZP-458 as a potential treatment of pediatric and adult patients with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) who are hypersensitive to E. coli-derived asparaginases. In October, the FDA granted a Fast Track designation to JZP-458 for treating the given patient population. […]

Stock Analysts

Myriad Genetics’ Cancer Companion Diagnostic Test Gets FDA Nod

Myriad Genetics, Inc. MYGN received the FDA clearance for its BRACAnalysis CDx, which is to be used as a companion diagnostic test by care providers to identify patients with metastatic pancreatic cancer. Notably, the identified patients will only be able to avail the test if they have a germline BRCA mutation and are eligible to be treated with PARP inhibitor Lynparza (olaparib). […]